Lauren B. Krupp, MD

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Tanuja Chitnis, MD and Lauren B. Krupp, MD give insight into the future of pediatric multiple sclerosis by discussing unmet needs and advice for community neurologists.

Expert neurologists discuss drugs in development for pediatric multiple sclerosis and consider the potential for biomarkers to monitor treatment response or new disease activity in the future.

Lauren B. Krupp, MD considers how treatment failure in pediatric multiple sclerosis may be defined as disease relapse, new or enlarging legions, inability to tolerate treatment, or lack of adherence.

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

Expert neurologist Lauren B. Krupp, MD provides insight into the use of diagnostic tools for pediatric multiple sclerosis such as MRI imaging, laboratory blood tests, and lumbar punctures.

Key opinion leaders in the management of MS comment on the current diagnostic criteria and discuss the importance of ruling out other common mimics in pediatric patients.

Lauren B. Krupp, MD provides insight into the signs and symptoms of multiple sclerosis and emphasizes differences in clinical presentation between adult and pediatric patients.

Thought leaders in neurology discuss the results of the phase 3 PARADIGMS trial as well as the safety and efficacy of fingolimod for use in pediatric patients with multiple sclerosis.

Tanuja Chitnis, MD provides an overview of genetic, environmental, and hormonal risk factors for pediatric multiple sclerosis and discusses its prevalence based on age, sex, and geographic location.